Solinacin (i.e. Solinacin Succinate) and Tolterodine (i.e. Tolterodine Tartrate) It is not possible to tell who is better, and the exact effect of the medication varies from person to person. Solifenacin Succinate and Tolterodine Tartrate are competitive muscarinic receptor antagonists, both of which can inhibit the overactivity of the urethra muscle, and are indicated for the treatment of urinary incontinence and/or urinary frequency and urgency in patients with overactive bladder syndrome. The common adverse effects of both drugs include dry mouth, constipation, nausea, dyspepsia, and abdominal pain. Contraindications for both drugs include hypersensitivity to the product, severe gastrointestinal disorders, myasthenia gravis, urinary retention, and patients with narrow-angle glaucoma, in addition to solifenacin succinate should be contraindicated in people undergoing hemodialysis, severe hepatic dysfunction, severe renal dysfunction or moderate hepatic dysfunction in people who are on potent cytochrome P4503A4 enzyme inhibitors such as ketoconazole. The above two drugs have the same indications, but there are individual differences in the organism, resulting in two drugs have their own applicable groups, can not judge whose effect is better, the specific use of drugs should follow the doctor’s instructions.